Use of a multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) for bacterial meningitis prevention

Multicomponent Meningococcal Serogroup B Vaccine (4CMenB; Bexsero®): A Review of its Use in Primary and Booster Vaccination

(2013) Natalie J. Carter   BIODRUGS

Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose

(2013) M. D. Snape et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

The price of prevention: what now for immunisation against meningococcus B?

(2013) Richard Moxon et al.   LANCET

Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials

(2013) Timo Vesikari et al.   LANCET

Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment

(2013) Ulrich Vogel et al.   LANCET INFECTIOUS DISEASES

Neisseria meningitidis serogroup B vaccine development

(2013) Nicole M. Caesar et al.   MICROBIAL PATHOGENESIS

Bactericidal Antibody Persistence 2 Years After Immunization With 2 Investigational Serogroup B Meningococcal Vaccines at 6, 8 and 12 Months and Immunogenicity of Preschool Booster Doses

(2013) Matthew D. Snape et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage

(2013) Giacomo Frosi et al.   VACCINE

Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB)

(2013) Julie A. Bettinger et al.   VACCINE

Letter from the Editor

(2013) Ronald W. Ellis et al.   Human Vaccines & Immunotherapeutics

Genetic characteristics ofNeisseria meningitidisserogroup B strains carried by adolescents living in Milan, Italy

(2013) Susanna Esposito et al.   Human Vaccines & Immunotherapeutics

Interlaboratory Standardization of the Sandwich Enzyme-Linked Immunosorbent Assay Designed for MATS, a Rapid, Reproducible Method for Estimating the Strain Coverage of Investigational Vaccines

(2012) Brian D. Plikaytis et al.   Clinical and Vaccine Immunology

Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules

(2012) Nicoletta Gossger et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study

(2012) María Elena Santolaya et al.   LANCET

Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?

(2012) Eva Hong et al.   VACCINE

Immunogenicity and Safety of a Multicomponent Meningococcal Serogroup B Vaccine and a Quadrivalent Meningococcal CRM197Conjugate Vaccine against Serogroups A, C, W-135, and Y in Adults Who Are at Increased Risk for Occupational Exposure to Meningococcal Isolates

(2010) Alan Kimura et al.   Clinical and Vaccine Immunology

Updated Postlicensure Surveillance of the Meningococcal C Conjugate Vaccine in England and Wales: Effectiveness, Validation of Serological Correlates of Protection, and Modeling Predictions of the Duration of Herd Immunity

(2010) H. Campbell et al.   Clinical and Vaccine Immunology

Review of Meningococcal Group B Vaccines

(2010) Dan M. Granoff   CLINICAL INFECTIOUS DISEASES

Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines

(2010) J. Donnelly et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus

(2010) Marzia M. Giuliani et al.   VACCINE

Mechanisms of meningeal invasion by a bacterial extracellular pathogen, the example of Neisseria meningitidis

(2009) Olivier Join-Lambert et al.   PROGRESS IN NEUROBIOLOGY

Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease

(2009) Carl E. Frasch et al.   VACCINE

Global epidemiology of meningococcal disease

(2009) Lee H. Harrison et al.   VACCINE